Advertisement

Experientia

, Volume 30, Issue 5, pp 456–458 | Cite as

3,4-Dihydroxyphenylacetic acid (DOPAC): a possible endogenous inhibitor of indoleamine-N-methylation in the rat brain

  • P. C. Waldmeier
  • L. Maitre
Article

Keywords

Clozapine Tryptamine Amyl Alcohol Fetal Urine Bufotenin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Résumé

L'acide dihydroxyphénylacétique (DOPAC) et l'acide homovanillique (HVA) inhibent la méthylation de la tryptamine par une méthylase partiellement purifiée du cerveau de rat. Les concentrations nécessaires à cette inhibition sont hautes et du même ordre de grandeur que celles qu'on peut attendre du métabolisme de la dopamine au niveau des terminaisons dopaminergiques. La chlorpromazine et la clozapine n'influencent pas cette activité enzymatique.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    P. Laduron, Nature, Lond.238, 212 (1972).CrossRefGoogle Scholar
  2. 2.
    L. L. Hsu andA. J. Mandell, Life Sci.13, 847 (1973).CrossRefPubMedGoogle Scholar
  3. 3.
    J. Leysen andP. Laduron, inAdvances in Biochemical. Pharmacology of Serotonin-New Vistas (Eds.E. Costa andM. Sandler; Raven Press, New York 1974), in press.Google Scholar
  4. 4.
    S. P. Banerjee andS. H. Snyder, Science182, 74 (1973).CrossRefPubMedGoogle Scholar
  5. 5.
    S. S. Kety, Fedn. Proc.20, 894 (1961).Google Scholar
  6. 6.
    H. E. Himwich, inBiochemistry, Schizophrenias and Affective Illnesses (The Williams R. Wilkins Co. Baltimore (1970), p. 79.Google Scholar
  7. 7.
    N. E. Andén, B. E. Roos andB. Werdinius, Life Sci.3, 149 (1964).CrossRefGoogle Scholar
  8. 8.
    L. Maitre, P. C. Waldmeier andP. A. Baumann, inFrontiers in Catecholamine Research (Eds.E. Usdin andS. H. Snyder; Pergamon Press, New York (1973) 1015.CrossRefGoogle Scholar
  9. 9.
    Ch. Warburg, Biochem. Z.310, 384 (1941).Google Scholar
  10. 10.
    G. F. Murphy, D. Robinson andD. F. Sharman, Br. J. Pharmac.36, 107 (1969).CrossRefGoogle Scholar
  11. 11.
    N. E. Andén, K. Fuxe, B. Hamberger andT. Hökfelt, Acta physiol. scand.67, 306 (1966).CrossRefPubMedGoogle Scholar
  12. 12.
    L. L. Iversen andN. J. Uretsky, Brain Res.24, 364 (1970).CrossRefPubMedGoogle Scholar
  13. 13.
    S. Roffler-Tarlow, D. F. Sharman andP. Tegerdine, Br. J. Pharmac.42, 343 (1971).CrossRefGoogle Scholar
  14. 14.
    W. C. Korevaar, M. A. Geyer, S. Knapp, L. L. Hsu andA. J. Mandell, Nature, Lond.245, 244 (1973).CrossRefGoogle Scholar
  15. 15.
    A. J. Mandell, S. Knapp andL. L. Hsu, Life Sci.14, 1 (1974).CrossRefPubMedGoogle Scholar
  16. 16.
    The skilful technical assistance of Mr.J. J. Feldtrauer is gratefully acknowledged.Google Scholar

Copyright information

© Birkhäuser-Verlag 1974

Authors and Affiliations

  • P. C. Waldmeier
    • 1
  • L. Maitre
    • 1
  1. 1.Research Department, Pharmaceuticals DivisionCiba-Geigy Ltd.BaselSwitzerland

Personalised recommendations